(4S,5S)-methyl 1-benzyl-4,5-dihydro-4-methyl-2,5-diphenyl-1H-imidazole-4-carboxylate | 1140519-19-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4S,5S)-methyl 1-benzyl-4,5-dihydro-4-methyl-2,5-diphenyl-1H-imidazole-4-carboxylate
• 英文别名: methyl (4S,5S)-3-benzyl-5-methyl-2,4-diphenyl-4H-imidazole-5-carboxylate
• CAS: 1140519-19-2
• 化学式: C₂₅H₂₄N₂O₂
• 分子量: 384.478
• InChiKey: BJSLNWYYIVOQJY-DHLKQENFSA-N

物化性质

• 沸点：
  522.9±60.0 °C(predicted)
• 密度：
  1.11±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  41.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4S,5S)-methyl 1-benzyl-4,5-dihydro-4-methyl-2,5-diphenyl-1H-imidazole-4-carboxylate 在 lithium aluminium tetrahydride 、 氯化铵 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.17h， 以57%的产率得到dl-((4S, 5S)-1-benzyl-4-methyl-2,5-diphenyl-4,5-dihydro-1H-imidazol-4-yl)-methanol
  参考文献：
  名称：

  [EN] SUBSTITUTED IMIDAZOLINE COMPOUNDS
  [FR] COMPOSÉS D'IMIDAZOLINE SUBSTITUÉS

  摘要：

  本发明涉及包括前药和其盐的取代咪唑啉化合物组合物。在某些实施例中，本发明涉及将这些组合物用作治疗剂，优选用于治疗关节炎或癌症。在进一步的实施例中，本发明涉及含有有效量的上述取代咪唑啉化合物的制药组合物，其作为遗传表达或与转录因子NF-ϰB相互作用的激动剂或拮抗剂发挥作用。

  公开号：

  WO2009048586A1
• 作为产物：
  描述：

  三甲基硅烷化重氮甲烷 、 dl-(4S,5S)-1-benzyl-4-methyl-2,5-diphenyl-4,5-dihydro-1H-imidazole-4-carboxylic acid 在 甲醇 作用下， 以 苯 为溶剂， 反应 3.0h， 以83%的产率得到(4S,5S)-methyl 1-benzyl-4,5-dihydro-4-methyl-2,5-diphenyl-1H-imidazole-4-carboxylate
  参考文献：
  名称：

  Structural–activity relationship study of highly-functionalized imidazolines as potent inhibitors of nuclear transcription factor-κB mediated IL-6 production

  摘要：

  We herein describe the synthesis and anti-inflammatory properties of a small library of imidazoline-based NF-kappa B inhibitors. The structure-activity relationship of various substituents on an imidazoline core structure was evaluated for the ability to inhibit NF-kappa B mediated IL-6 production. Optimization of the scaffolds was pursued by correlating luciferase-based NF-kappa B reporter assays with inhibition of IL-6 production in IL-1 beta stimulated human blood. Several derivatives were found to inhibit NF-kappa B mediated IL-6 production in the nanomolar range in IL-1 beta stimulated human blood. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.03.002

文献信息

• Substituted Imidazoline Compounds
  申请人：Tepe Jetze

  公开号：US20090156830A1

  公开（公告）日：2009-06-18

  The invention relates to compositions comprising substituted imidazoline compounds including prodrugs, and salts thereof. In some embodiments, the invention relates to the use of these compositions as therapeutic agents, preferably for the treatment of arthritis or cancer. In further embodiments, The invention relates to the pharmaceutical compositions with effective amounts of substituted imidazoline compounds disclosed herein that function as agonist or antagonists of the genetic expression or interactions with transcription factor NF-κB.
• US8252942B2
  申请人：——

  公开号：US8252942B2

  公开（公告）日：2012-08-28